… [摘要] 目的分析表皮生长因子受体(epidermal growth factor receptor,EGFR)非第18⁃21 四个
外显子 (exons⁃18⁃21,Ex18⁃21)突变晚期非小细胞肺癌(non⁃small cell lung cancer,NSCLC)…

… 目前晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的主要治疗方法为包括化疗和靶
… inhibitors, EGFR-TKIs）吉非替尼（gefitinib）和厄洛替尼（erlotinib）已成为标准治疗之一 [2-4] ，而…

… 靶向治疗已经成为晚期非小细胞肺癌（non-small cell lung cancer, … Gefitinib versus erlotinib
as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung …

… Gefitinib versus cisplatin plus docetaxel in patients with non-smallcell lung cancer harbouring
mutations of the epidermal … Erlotinib as maintenance treatment in advanced non-small-…

… 替尼治疗非小细胞肺癌（non-small cell lung cancer, NSCLC）的优势人群和耐药发生这一研究
结果 [1] ，设计对含铂方案化疗失败后选择吉非替尼（gefitinib）治疗的患者根据SELDI蛋白质指纹…

… erlotinib for patients with advanced stage non⁃small⁃cell … Maintenance therapy …
Combined gefitinib and peme⁃ trexed …

… )and Erlotinib treatment in patients with non⁃small cell lung … after response to gefitinib in
non⁃small⁃cell lung cancer[J]. … dose erlotinib for refractory brain metastases in a patient with …

… Erlotinib versus standard chemotherapy as first-line … and clinical outcome of advanced
nonsmall cell lung cancer[J]. … by gefitinib maintenance therapy versus gefitinib monotherapy in …

… 试验[61]中,研究了erlotinib用于复治的进展期 NSCLC患者的疗效,结果erlotinib… Gefitinib plus
best supportive care in previously treated patients with refractory advanced non-smallcell lung …

… for the first- and second-line treatment of non-small cell lung cancer (NSCLC). However,
the role of pemetrexed therapy in the third-line and beyond treatment of NSCLC has yet to be …